{
    "clinical_study": {
        "@rank": "78981", 
        "arm_group": [
            {
                "arm_group_label": "Telmisartan+amlodipine+HCTZ", 
                "arm_group_type": "Experimental", 
                "description": "telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet"
            }, 
            {
                "arm_group_label": "Telmisartan+amlodipine", 
                "arm_group_type": "Active Comparator", 
                "description": "telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-centre, randomised, double-blind, active-controlled, parallel-group\n      comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg\n      +hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+\n      amlodipine 5 mg (T80/A5 mg) in blood pressure lowering effect at week 8, the end of the\n      double-blind period in essential hypertensive patients who fail to respond adequately to\n      telmisartan 80 mg+ amlodipine 5 mg. Patients are assigned to one of the two groups after a\n      6-week open-label run-in period taking T80/A5 mg."
        }, 
        "brief_title": "Add-on to Micamlo BP Trial", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs\n             and mean seated diastolic blood pressure (DBP) must be >=90 and <=114 mmHg and mean\n             seated systolic blood pressure (SBP) must be =<200 mmHg\n\n          -  Able to stop all current antihypertensive drugs (other than study medication) from\n             Visit 1b through the end of the trial without risk to the patient based on the\n             investigator's opinion\n\n          -  Age 20 years or older\n\n        Exclusion criteria:\n\n          -  Patients with known or suspected secondary hypertension\n\n          -  Patients with clinically relevant cardiac arrhythmia\n\n          -  Congestive heart failure with New York Heart Association (NYHA) functional class\n             III-IV\n\n          -  Patients with recent cardiovascular events\n\n          -  Patients with recent stroke events\n\n          -  Patients with a history of sudden deterioration of renal function with angiotensin II\n             receptor blockers or angiotensin converting enzyme inhibitors; or patients with\n             post-renal transplant or post-nephrectomy\n\n          -  Patients with hepatic and/or renal dysfunction\n\n          -  Pre-menopausal women who are nursing or pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975246", 
            "org_study_id": "1348.1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Telmisartan+amlodipine+HCTZ", 
                "description": "FDC tablet", 
                "intervention_name": "Telmisartan + amlodipine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Telmisartan+amlodipine+HCTZ", 
                "description": "tablet", 
                "intervention_name": "hydrochlorothiazide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Telmisartan+amlodipine", 
                "description": "FDC tablet", 
                "intervention_name": "Telmisartan + amlodipine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Telmisartan+amlodipine", 
                "description": "placebo matching hydrochlorothiazide tablet", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydrochlorothiazide", 
                "Amlodipine", 
                "Telmisartan", 
                "Benzoates"
            ]
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Atsubetsu-ku,Sapporo,Hokkaido", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.015 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bunkyo-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.006 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiyoda-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.002 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiyoda-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.031 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiyoda-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.005 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.030 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.033 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku,Sapporo,Hokkaido", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.016 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku,Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.021 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Itabashi-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.024 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Itoshima, Fukuoka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.028 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Katsushika-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.027 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kishiwada, Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.001 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kita-ku, Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.009 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kita-ku, Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.029 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiyose,Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.014 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koto-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.003 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mihama-ku, Chiba, Chiba", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.022 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miyagino-ku, Sendai, Miyagi", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.004 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moriya, Ibaraki", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.017 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Naka-ku,Yokohama,Kanagawa", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.013 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nishi-ku, Fukuoka, Fukuoka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.018 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Okinawa, Okinawa", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.007 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sakaide, Kagawa", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.020 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo, Hokkaido", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.026 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo, Hokkaido", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.025 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita, Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.032 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita, Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.008 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Takamatsu, Kagawa", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.019 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toshima-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.1.023 Boehringer Ingelheim Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period", 
            "safety_issue": "No", 
            "time_frame": "baseline and week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975246"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period", 
                "safety_issue": "No", 
                "time_frame": "baseline and week 8"
            }, 
            {
                "measure": "The proportion of patients with DBP<90 mmHg and SBP<140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period", 
                "safety_issue": "No", 
                "time_frame": "baseline and week 8"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}